Ribavirin reduces clinical signs and pathological changes of experimental autoimmune encephalomyelitis in Dark Agouti rats.

@article{Milicevic2003RibavirinRC,
  title={Ribavirin reduces clinical signs and pathological changes of experimental autoimmune encephalomyelitis in Dark Agouti rats.},
  author={Irena Milicevic and Sanja Pekovi{\'c} and Sanja Subasi{\'c} and Marija Mostarica-Stojkovi{\'c} and Stanislava D. Sto{\vs}i{\'c}-Gruji{\vc}i{\'c} and Ljubica Medi{\'c}-Mija{\vc}evi{\'c} and Vjera M Pejanovic and Ljubisav Raki{\'c} and Mirjana B. Stojiljkovi{\'c}},
  journal={Journal of neuroscience research},
  year={2003},
  volume={72 2},
  pages={268-78}
}
The effect of ribavirin on development of experimental autoimmune encephalomyelitis (EAE) was investigated. The disease was induced in genetically susceptible Dark Agouti rats with syngeneic spinal cord homogenate in complete Freund's adjuvant (SCH-CFA). Depending on the amount of mycobacteria in CFA, the animals developed either moderate or severe EAE. Ribavirin (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) was applied i.p. at a daily dosage of 30 mg/kg in two treatment protocols: from… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

Similar Papers

Loading similar papers…